Construction of a TTN Mutation-Based Prognostic Model for Evaluating Immune Microenvironment, Cancer Stemness, and Outcomes of Colorectal Cancer Patients

Figure 5

ISS as a predictor of patient prognosis in the validation cohorts: (a) distribution of high- and low-ISS groups in the GSE17536 cohort; (b) comparison of patient prognosis between the high- and low-ISS groups of the GSE17536 cohort; (c) ROC curve for ISS in the GSE17536 cohort; (d) distribution of the high- and low-ISS groups in the GSE38832 cohort; (e) comparison of patient prognosis in the high- and low-ISS groups of the GSE38832 cohort; (f) ROC curve for ISS in the GSE38832 cohort; (g) distribution of the high- and low-ISS groups in the GSE39582 cohort; (h) comparison of patient prognosis between the high- and low-ISS groups of the GSE39582 cohort; (i) ROC curve for ISS in the GSE39582 cohort.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)